ERBB2 and breast carcinoma: The rapamycin analogs CCI-779 (temsirolimus) and RAD001 (everolimus) are approved for the clinical treatment of advanced renal cell carcinoma [28], progressive neuroendocrine tumors of pancreatic origin [29], subependymal giant cell astrocytoma associated with tuberous sclerosis [30], and more recently for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with the aromatase inhibitor exemestane [31].